NCT03896737: Phase 2: EMN 18 - Dara-VCd VS VTd Then Maintenance With Ixazomib (IXA) or IXA-Dara
EMN 18 Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib...
top of page
Dec 11, 2019
NCT04035226 - Study of Real-life Current Standards of Care in Patients With RRMM with 3 prior lines
LocoMMotion Relapsed & Refractory Multiple Myeloma NCT04035226: A Study of Real-life Current Standards of Care in Patients With Relapsed...
185
Dec 20, 2018
NCT03562169: Phase 3: Ixazomib in Autologous Stem Cell Transplant in RRMM Myeloma XII (ACCoRd)
NCT03562169: Phase 3: The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd) NCT03562169:...
82
Dec 7, 2018
NCT01554852: Phase 3- Thalidomide, Lenalidomide, Carfilzomib, Bortezomib, Vorinostat-NDMM Myeloma XI
Myeloma XI The purpose of this study is to compare a standard chemotherapy regimen of cyclophosphamide, dexamethasone plus thalidomide...
390
Dec 13, 2016
NCT02891811: Phase 2: Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction
NCT02891811: Phase 2: Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono...
90
Dec 31, 2015
NCT02541383: Phase 3 - Bortezomib, thalidomide, dex +/-Daratumumab before & after ASCT (CASSIOPEIA)
The CASSIOPEIA trial IFM / HOVON IFM 2015-01 HOVON HO131 MM Newly Diagnosed Multiple Myeloma A Study to Evaluate Daratumumab in...
684
Dec 5, 2013
NCT01971658: Phase 3: Efficacy Study Comparing VTD Versus VCD as Induction NDMM - IFM2013-04
IFM2013-04 NCT01971658: Phase 3: Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone...
231
Dec 9, 2010
NCT01134484: Phase 3 - VELCADE-Thal-Dex (VTD) vs Thal-Dex (TD) Incorporated Into Double ASCT NDMM
GIMEMA-MMY-3006 Study GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto Italian Myeloma Network). VELCADE-Thalidomide-Dexametha...
108
Dec 29, 2008
NCT00734877: UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myel
Toward improving the therapeutic index of standard TT3 (S-TT3), the investigators will employ a randomized Phase III trial design to...
426
Dec 14, 2008
NCT00689936: Phase 3 - Lenalidomide+low dose dex vs Melphalan, Prednisone, Thalidomide in NDMM FIRST
FIRST study IFM 07-01 CC-5013-MM020 Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan,...
440
Dec 6, 2008
NCT00602641: Phase 3: Melphalan, Prednisone, and Thalidomide or Lenalidomide in NDMM Myeloma
ECOG-E1A06 ECOG-ACRIN Cancer Research Group NCT00602641: Phase 3: Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating...
67
Dec 14, 2007
NCT00461747: Phase 3 - GEM05 for Patients With Multiple Myeloma Under 65 Years (GEM05MENOS65)
GEM05 GEM05MENOS65 PETHEMA/GEM Spanish Myeloma Group GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica...
314
Dec 12, 2007
NCT00572169: UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy.
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy. With this study - Total Therapy IIIB - researchers are...
351
Dec 8, 2007
Incorporating bortezomib into upfront treatment for multiple myeloma: early results total therapy 3
Br J Haematol 2007 Jul Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 Bart...
158
Dec 7, 2007
Bortezomib before & after high-dose therapy in myeloma: phase III HOVON-65/GMMG-HD4 trial
HOVON-65/GMMG-HD4 trial Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4...
233
Dec 7, 2007
NCT00573391: Phase 3: Study of Multiple Myeloma Patients Relapsing or Progressing After ASCT -TT2
NCT00573391: Phase 3: Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2...
127
Dec 6, 2007
NCT00507416: Phase 3: Velcade,Thalidomide, Dexamethasone Vs Velcade, Dexamethasone Vs VMP (UPFRONT)
UPFRONT NCT00507416: Phase 3: Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and...
201
Dec 8, 2006
NCT00367185: Phase 3 - Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma
IFM 99-06 NCT00367185: Phase 3 - Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma In multiple myeloma, combination...
110
Dec 10, 2004
NCT00083551: UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma
This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after...
268
Dec 9, 2004
NCT00081939: UARK 2003-33, Total Therapy III
UARK 2003-33, Total Therapy III Total Therapy 3 The UARK 2003-33, Total Therapy III - There have been two previous Total Therapy studies...
257
Dec 9, 2004
NCT00098475: Phase 3: Lenalidomide and Dexamethasone With or Without Thalidomide in Multiple Myeloma
ECOG-ACRIN Cancer Research Group ECOG E4A03 NCT00098475: Phase 3: Lenalidomide and Dexamethasone With or Without Thalidomide in Treating...
274
Dec 3, 2004
NCT00028886: Phase 3 - Combination Chemotherapy With or Without Thalidomide in Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may...
323
Dec 16, 2000
Phase 2: Antitumor Activity of Thalidomide in Refractory Multiple Myeloma - NEJM 1999
Time Frame: December 1997 and June 1998 Phase 2: Antitumor Activity of Thalidomide in Refractory Multiple Myeloma - NEJM 1999 Antitumor...
106
bottom of page